EDMONTON, AB, Jan. 23, 2024 /CNW/ - Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the "Company") a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, announced that it has received information that the Phase III clinical trial of oregovomab for the treatment of Ovarian Cancer, sponsored by CanariaBio Inc ("CAB"), has received recommendations from the Data Safety Monitoring Board (DSMB), an independent committee appointed by CAB to advise on the trials, to discontinue the clinical trial after conducting a futility evaluation for interim progression free survival in study subjects.
Read more at newswire.caOregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.
